A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 480 participants.
Also called NCT07693777
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 480 participants
- Registry
-
NCT07693777
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07693777. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-17 (anticipated); primary completion 2029-02-14 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
- Condition
- Severe Hypertriglyceridemia (sHTG)
- Condition
- Hypertriglyceridemia
- Intervention (Biological)
- DR10624 Injection
- Intervention (Other)
- Matching Placebo for DR10624
- Lead sponsor
- Zhejiang Doer Biologics Co., Ltd.
Record details
- Record id
cardio:ct-nct07693777- Content hash
cb899d130b83131b4fb635a8e241661858d0c1c999179d05fc44084784c565df